Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic, discussed Mayo Clinic’s new blood test that helps combat the leading cause of death in the U.S. on Voice of America.
Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic, discussed Mayo Clinic’s new blood test that helps combat the leading cause of death in the U.S. with KTTC. Read this post to view the story.
A new type of blood test may help physicians identify which patients with and without evidence of coronary blockages are at risk for heart attacks and strokes. Even individuals with normal levels of low-density lipoprotein (LDL), known as the so-called “bad” cholesterol, but still at risk, seem to be identified.
This week’s Research Roundup highlights the clinical and pathological evolution of giant cell arteritis with a prospective study of follow-up temporal artery biopsies in 40 treated patients.
ST2 is a biomarker of fibrosis and cardiac remodeling and provides clinicians with significant prognostic guidance without being adversely influenced by typical confounders such as age, obesity, and renal impairment.
Mayo Clinic has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease. The test measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.
Mayo Medical Laboratories has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease. A recent article in Clinical Lab Products takes a closer look at the test.
Plasma ceramides are predictors of adverse cardiovascular events resulting from unstable atherosclerotic plaque. Three specific ceramides have been identified as highly linked to cardiovascular disease and insulin resistance: Cer16:0, Cer18:0, and Cer24:1. Jeff Meeusen, Ph.D., provides a video overview of this new test.
According to a recent article in CAP TODAY, laboratories and hospitals in the U.S. continue to look forward to high-sensitivity troponin assays. Many medical professionals throughout the country weighed in with their anticipation and predictions, including Allan Jaffe, M.D., Professor of Medicine and Cardiology and Professor of Laboratory Medicine and Pathology at the Mayo Clinic in Rochester, Minnesota.
In the cover story of the May issue of CAP TODAY, Joseph Maleszewski, M.D., Supervisor of Cardiovascular Pathology at the Mayo Clinic in Rochester, Minnesota, discusses the complexities of cardiovascular pathology cases and the use of endomyocardial biopsy for diagnosis.
Zora Biosciences Oy, a diagnostics discovery company specializing in cardiovascular disease, and Mayo Medical Laboratories recently signed an agreement to collaborate on a new test for plasma ceramides.
Cytochrome P450 2C19 (encoded by the gene CYP2C19) is a liver enzyme that participates in the activation of the anticoagulant clopidogrel (Plavix) and metabolism of other drugs, such as citalopram. As a result, Clopidrigrel may be less effective in altering platelet activity in those people, who may remain at risk for heart attack, stroke, and cardiovascular death.